Alian Al-Balas1,2, Rakesh Varma2, Kedar Sharbidre2, Hassan Al-Balas3,4, Ammar Almehmi1,2, Ahmed Kamel Abdel Aal5, Michelle L Robbin2, Michael Allon1. 1. Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama. 2. Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama. 3. Division of Interventional Radiology, Baylor College of Medicine, Houston, Texas. 4. Division of Radiology, Jordan University of Science & Technology, Irbid, Jordan. 5. Division of Interventional Radiology, University of Texas at Houston, Houston, Texas.
Abstract
Background: The first endovascular arteriovenous fistula (endoAVF) device (WavelinQ), a novel percutaneous technique of AVF creation, was approved by the Food and Drug Administration in 2018 and has been placed in a small number of United States patients on hemodialysis. It is unknown how often patients with advanced CKD have vascular anatomy suitable for WavelinQ creation. The goal of this study was to determine the proportion of patients with vascular anatomy suitable for WavelinQ creation and to assess patient characteristics associated with such suitability. Methods: All patients referred for vascular access placement at a large academic medical center underwent standardized preoperative sonographic vascular mapping to assess suitability for an AVF. During a 2-year period (March 2019 to March 2021), we assessed the suitability of the vessels for creation of WavelinQ. We then compared the demographic characteristics, comorbidities, and vascular mapping measurements between patients who were or were not suitable for WavelinQ. Results: During the study period, 437 patients underwent vessel mapping. Of these, 51% of patients were eligible for a surgical AVF, and 32% were eligible for a WavelinQ AVF; 63% of those suitable for a surgical AVF were also suitable for a WavelinQ AVF. Patients with a vascular anatomy suitable for WavelinQ were younger (age 55±15 versus 60±14 years, P=0.01) but similar in sex, race, diabetes, hypertension, coronary artery disease, and peripheral artery disease. Conclusions: Among patients with CKD with vascular anatomy suitable for a surgical AVF, 63% are also suitable for a WavelinQ endoAVF. Older patients are less frequently suitable for WavelinQ.
Background: The first endovascular arteriovenous fistula (endoAVF) device (WavelinQ), a novel percutaneous technique of AVF creation, was approved by the Food and Drug Administration in 2018 and has been placed in a small number of United States patients on hemodialysis. It is unknown how often patients with advanced CKD have vascular anatomy suitable for WavelinQ creation. The goal of this study was to determine the proportion of patients with vascular anatomy suitable for WavelinQ creation and to assess patient characteristics associated with such suitability. Methods: All patients referred for vascular access placement at a large academic medical center underwent standardized preoperative sonographic vascular mapping to assess suitability for an AVF. During a 2-year period (March 2019 to March 2021), we assessed the suitability of the vessels for creation of WavelinQ. We then compared the demographic characteristics, comorbidities, and vascular mapping measurements between patients who were or were not suitable for WavelinQ. Results: During the study period, 437 patients underwent vessel mapping. Of these, 51% of patients were eligible for a surgical AVF, and 32% were eligible for a WavelinQ AVF; 63% of those suitable for a surgical AVF were also suitable for a WavelinQ AVF. Patients with a vascular anatomy suitable for WavelinQ were younger (age 55±15 versus 60±14 years, P=0.01) but similar in sex, race, diabetes, hypertension, coronary artery disease, and peripheral artery disease. Conclusions: Among patients with CKD with vascular anatomy suitable for a surgical AVF, 63% are also suitable for a WavelinQ endoAVF. Older patients are less frequently suitable for WavelinQ.
Authors: M Allon; R Bailey; R Ballard; M H Deierhoi; K Hamrick; R Oser; V K Rhynes; M L Robbin; S Saddekni; S T Zeigler Journal: Kidney Int Date: 1998-02 Impact factor: 10.612
Authors: Jeffrey E Hull; William C Jennings; Randy I Cooper; Umar Waheed; Matthew E Schaefer; Rajeev Narayan Journal: J Vasc Interv Radiol Date: 2017-12-21 Impact factor: 3.464
Authors: M Allon; M E Lockhart; R Z Lilly; M H Gallichio; C J Young; J Barker; M H Deierhoi; M L Robbin Journal: Kidney Int Date: 2001-11 Impact factor: 10.612